Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
2. Dextofisopam
3. Egyt-341
4. Grandaxin
5. Levotofisopam
6. Tofizopam
1. 22345-47-7
2. Grandaxin
3. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
4. Emandaxin
5. Egyt 341
6. Tofisopamum
7. Uzc80hau42
8. Seriel
9. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-
10. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-benzo[d][1,2]diazepine
11. Tofizopam
12. Ncgc00165912-02
13. Benzodiazepine; Egyt 341; Grandaxin; Nodeprine; Seriel
14. Tofisopamum [inn-latin]
15. Tofisopam [inn:dcf:jan]
16. 82059-50-5
17. Einecs 244-922-3
18. Unii-uzc80hau42
19. Ccris 8738
20. Emandaxin (tn)
21. 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5h-2,3-benzodiazepine
22. Tofisopam [inn]
23. Tofisopam [jan]
24. Tofisopam [mi]
25. Dsstox_cid_3681
26. Tofisopam (jp17/inn)
27. Tofisopam [mart.]
28. Tofisopam [who-dd]
29. Dsstox_rid_77145
30. Dsstox_gsid_23681
31. Schembl43522
32. Tofisopam (patented In Japan)
33. Chembl404216
34. Schembl8086894
35. Dtxsid3023681
36. Chebi:32241
37. Bcp09600
38. Hy-a0165
39. Tox21_112269
40. Tofisopam, >=98% (hplc), Solid
41. Akos025401672
42. Db08811
43. Sb17495
44. Sb17496
45. Ncgc00165912-01
46. Ncgc00165912-03
47. Ac-24288
48. Ls-14948
49. Cas-22345-47-7
50. Db-045872
51. Ft-0638212
52. T3509
53. D01254
54. 345t477
55. A878592
56. Q945537
57. Q-201839
58. Brd-a69095630-001-01-1
59. 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine
60. 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5h-2,3-benzodiazepine
61. (+/-)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
62. (1z,3z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-benzo[d][1,2]diazepine
Molecular Weight | 382.5 g/mol |
---|---|
Molecular Formula | C22H26N2O4 |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 382.18925731 g/mol |
Monoisotopic Mass | 382.18925731 g/mol |
Topological Polar Surface Area | 61.6 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 579 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of anxiety and alcohol withdrawal.
Like other benzodiazepines, tofisopam possesses anxiolytic properties but unlike other benzodiazepines it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties. It enhances the anticonvulsant activity of 1,4-benzodiazepines like diazepam but not sodium valproate, carbamazepine, phenobarbital, or phenytoin.
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
N - Nervous system
N05 - Psycholeptics
N05B - Anxiolytics
N05BA - Benzodiazepine derivatives
N05BA23 - Tofisopam
Hepatic.
6-8 hours
Tofisopam does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor. One study (Rundfeldt C. et al.) has shown that tofisopam acts as an isoenzyme-selective inhibitor of phosphodiesterases (PDEs) with highest affinity to PDE-4A1 (0.42 M) followed by PDE-10A1 (0.92 M), PDE-3 (1.98 M) and PDE-2A3 (2.11 M).
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Registration Number : 219MF10297
Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY
Initial Date of Registration : 2007-09-18
Latest Date of Registration :
Registrant Name : Hwanin Pharmaceutical Co., Ltd.
Registration Date : 2011-10-14
Registration Number : 20050831-64-C-192-03(1)
Manufacturer Name : Egis Pharmaceuticals PLC (Egis Pharmaceuticals Private Limited Company)
Manufacturer Address : H-1106 Budapest Kereszturi ut 30-38, Hungary
Available Reg Filing : ASMF |
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-64-C-192-03
Manufacturer Name : Egis Pharmaceuticals PLC (Egis Pharmaceuticals Private Limited Company)
Manufacturer Address : H-1106 Budapest Kereszturi ut 30-38, Hungary
Available Reg Filing : ASMF |
Date of Issue : 2022-10-17
Valid Till : 2025-08-08
Written Confirmation Number : WC-0382
Address of the Firm :
Registrant Name : Pampia Co., Ltd.
Registration Date : 2021-12-30
Registration Number : 20211230-64-C-396-06
Manufacturer Name : Symed Labs Ltd(Unit-I)
Manufacturer Address : Sy. No. 353, Domadugu Village Gummadidala (Mandal), Sangreddy District Telangana State, India
Registrant Name : Samhwa Biopharm Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-64-C-190-01
Manufacturer Name : Samhwa Biopharm Co., Ltd.
Manufacturer Address : 150 Hyeop-ro, Siheung-si, Gyeonggi-do
Registrant Name : Hanseochem Co., Ltd.
Registration Date : 2010-06-16
Registration Number : 20100616-64-C-272-04
Manufacturer Name : Hanseochem Co., Ltd.
Manufacturer Address : 41 Poseung Industrial Complex-ro, Poseung-eup, Pyeongtaek-si, Gyeonggi-do
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2015-09-24
Registration Number : 20050831-64-C-191-02(3)
Manufacturer Name : Sanyo Chemical Laboratories Co., Ltd. Toyama Factory
Manufacturer Address : 1-5-1, Yasuuchi, Yatsuo-Machi, Toyama-Shi, Toyama, 939-2366, Japan
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
87
PharmaCompass offers a list of Tofisopam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tofisopam manufacturer or Tofisopam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tofisopam manufacturer or Tofisopam supplier.
PharmaCompass also assists you with knowing the Tofisopam API Price utilized in the formulation of products. Tofisopam API Price is not always fixed or binding as the Tofisopam Price is obtained through a variety of data sources. The Tofisopam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A dextofisopam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of dextofisopam, including repackagers and relabelers. The FDA regulates dextofisopam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. dextofisopam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of dextofisopam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A dextofisopam supplier is an individual or a company that provides dextofisopam active pharmaceutical ingredient (API) or dextofisopam finished formulations upon request. The dextofisopam suppliers may include dextofisopam API manufacturers, exporters, distributors and traders.
click here to find a list of dextofisopam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The dextofisopam Drug Master File in Japan (dextofisopam JDMF) empowers dextofisopam API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the dextofisopam JDMF during the approval evaluation for pharmaceutical products. At the time of dextofisopam JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of dextofisopam suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a dextofisopam Drug Master File in Korea (dextofisopam KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of dextofisopam. The MFDS reviews the dextofisopam KDMF as part of the drug registration process and uses the information provided in the dextofisopam KDMF to evaluate the safety and efficacy of the drug.
After submitting a dextofisopam KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their dextofisopam API can apply through the Korea Drug Master File (KDMF).
click here to find a list of dextofisopam suppliers with KDMF on PharmaCompass.
A dextofisopam written confirmation (dextofisopam WC) is an official document issued by a regulatory agency to a dextofisopam manufacturer, verifying that the manufacturing facility of a dextofisopam active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting dextofisopam APIs or dextofisopam finished pharmaceutical products to another nation, regulatory agencies frequently require a dextofisopam WC (written confirmation) as part of the regulatory process.
click here to find a list of dextofisopam suppliers with Written Confirmation (WC) on PharmaCompass.
dextofisopam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of dextofisopam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right dextofisopam GMP manufacturer or dextofisopam GMP API supplier for your needs.
A dextofisopam CoA (Certificate of Analysis) is a formal document that attests to dextofisopam's compliance with dextofisopam specifications and serves as a tool for batch-level quality control.
dextofisopam CoA mostly includes findings from lab analyses of a specific batch. For each dextofisopam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
dextofisopam may be tested according to a variety of international standards, such as European Pharmacopoeia (dextofisopam EP), dextofisopam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (dextofisopam USP).